Results 31 to 40 of about 19,188,679 (307)

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Bertagnolio Silvia, Lundgren Jens, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, Jens Lundgren (146550), Jordan Michael R.   +31 more
core   +2 more sources

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

, 2020
Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia (CLL) in the era of novel agents.
Kater, Arnon P., van der Straten, Lina, Levin, Mark-David, van den Broek, Esther C., Dinmohamed, Avinash G., Doorduijn, Jeanette K., Posthuma, Eduardus F. M.   +6 more
core   +1 more source

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Technau K., Olivia Keiser, Rabie, Helena, Giddy, Janet, Egger, Matthias, Davies M.-A., Eley, Brian, Van Cutsem, Gilles, Harry Moultrie, Janet Giddy, Karl Technau, Moultrie H., Helena Rabie, Eley B., Giddy J., Egger M., Robin Wood, Technau, Karl, Rabie H., Van Cutsem G., Gilles Van Cutsem, Matthias Egger, Keiser, Olivia, Brian Eley, Moultrie, Harry, Boulle, Andrew, Mary-Ann Davies, Davies, Mary-Ann, Andrew Boulle, Boulle A., Keiser O., Wood R., Wood, Robin   +32 more
core   +3 more sources

Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting

, 2021
Background: Colorectal cancer is the third most common cancer diagnosed in Australia. Although a large portion (46.4%) present at an early stage, up to 45% relapse and many others present with de novo metastatic disease.1, 2 Although the treatment ...
Ups, Katherine, Ryan, Elizabeth G, Francesconi, Alessandra   +2 more
core   +1 more source

Second line anti-cancer therapy for metastatic colorectal cancer: treatment strategy

Медицинский совет, 2015
Colorectal cancer is one of the most widespread cancers globally. Over the past decade, there has been a significant progress in the treatment of metastatic colorectal cancer.
K. A. Vorontsova, N. V. Dobrova, G. V. Vyshinskaya   +2 more
doaj   +1 more source

Cholangiocarcinoma: the quest for a second-line systemic treatment

Translational Cancer Research, 2019
Biliary tract cancers (BTC) are a heterogeneous group of epithelial neoplasms, with a poor prognosis. Advanced BTC remains a challenging, non-curable disease. Gemcitabine plus platinum chemotherapy is the standard of care as first-line (L1) therapy in this setting. Beyond failure of L1, available evidence to guide therapeutic decisions is scarce.
Vienot, Angélique, Neuzillet, Cindy
openaire   +2 more sources

Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis

Global Health Research and Policy, 2019
Background Antiretroviral therapy (ART) restores immune function and reduces human immunodeficiency virus (HIV) related adverse outcomes. The results of previous studies in Ethiopia were replete with inconsistent findings; nonexistence of national ...
Moges Agazhe Assemie, Muluneh Alene, Daniel Bekele Ketema, Selishi Mulatu   +3 more
doaj   +1 more source

Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

BMC Medicine, 2018
Background For patients starting treatment for depression, current guidelines recommend titrating the antidepressant dosage to the maximum of the licenced range if tolerated.
Tadashi Kato, Toshi A. Furukawa, Akio Mantani, Ken’ichi Kurata, Hajime Kubouchi, Susumu Hirota, Hirotoshi Sato, Kazuyuki Sugishita, Bun Chino, Kahori Itoh, Yoshio Ikeda, Yoshihiro Shinagawa, Masaki Kondo, Yasumasa Okamoto, Hirokazu Fujita, Motomu Suga, Shingo Yasumoto, Naohisa Tsujino, Takeshi Inoue, Noboru Fujise, Tatsuo Akechi, Mitsuhiko Yamada, Shinji Shimodera, Norio Watanabe, Masatoshi Inagaki, Kazuhira Miki, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Aran Tajika, Kiyomi Shinohara, Naohiro Yonemoto, Shiro Tanaka, Qi Zhou, Gordon H. Guyatt, for the SUN☺D Investigators   +35 more
doaj   +1 more source

Combinations of second-line treatment.

, 2019
Combinations of second-line treatment.
Magdalena Piróg (6281519), Lubomir Bodnar (6281510), Dorota Babczyk (6281516), Tomasz Basta (6281501), Robert Jach (6281531), Anna Horbaczewska (6281528), Paweł Knapp (6281504), Iwona Gawron (6281513), Paweł Blecharz (6281507), Anna Markowska (6281525), Tomasz Kluz (6281522)   +10 more
core   +1 more source